Official Journal. Information and Notices 19 November 2019 INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

16 

Loading....

Loading....

Loading....

Loading....

Loading....

Full text

(1)

Contents

II Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2019/C 392/01 Non-opposition to a notified concentration (Case M.9548 — Apollo Capital Management/Covivio/Hilton Kilmainham) (1)

. . . 1

2019/C 392/02 Non-opposition to a notified concentration (Case M.9570 — Bridgepoint/Latour/Primonial) (1)

. . . 2

2019/C 392/03 Non-opposition to a notified concentration (Case M.9509 — Warburg Pincus/CDPQ/Allied Universal) (1)

. . . 3

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

Council

2019/C 392/04 Notice for the attention of the persons subject to the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia. . . 4

2019/C 392/05 Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures directed against certain persons, entities and bodies in view of the situation in Tunisia apply. . . 5

European Commission

2019/C 392/06 Euro exchange rates — 18 November 2019. . . 6

EN

C 392

Official Journal

of the European Union

Volume 62

Information and Notices

19 November 2019

English edition

(2)

2019/C 392/07 Special Report No 21/2019 ‘Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU’. . . 7

2019/C 392/08 Special Report No 24/2019 ‘Asylum, relocation and return of migrants: Time to step up action to address disparities between objectives and results’ . . . 8

V Announcements

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION POLICY

European Commission

2019/C 392/09 Prior notification of a concentration (Case M.9639 — CDC/EDF/Dalkia Investissement) Candidate case for simplified procedure (1). . . 9

2019/C 392/10 Prior notification of a concentration (Case M.9343 — Hyundai Heavy Industries/Daewoo Shipbuilding & Marine Engineering) (1). . . 11

2019/C 392/11 Prior notification of a concentration (Case M.9461 — AbbVie/Allergan) (1). . . 12

(3)

II

(Information)

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES

AND AGENCIES

EUROPEAN COMMISSION

Non-opposition to a notified concentration

(Case M.9548 — Apollo Capital Management/Covivio/Hilton Kilmainham)

(Text with EEA relevance) (2019/C 392/01)

On 8 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1).

The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9548. EUR-Lex is the online access to European law.

(4)

Non-opposition to a notified concentration (Case M.9570 — Bridgepoint/Latour/Primonial)

(Text with EEA relevance) (2019/C 392/02)

On 11 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1).

The full text of the decision is available only in French and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9570. EUR-Lex is the online access to European law.

(5)

Non-opposition to a notified concentration (Case M.9509 — Warburg Pincus/CDPQ/Allied Universal)

(Text with EEA relevance) (2019/C 392/03)

On 11 November 2019, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1).

The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32019M9509. EUR-Lex is the online access to European law.

(6)

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND

AGENCIES

COUNCIL

Notice for the attention of the persons subject to the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive measures

directed against certain persons, entities and bodies in view of the situation in Tunisia (2019/C 392/04)

The following information is brought to the attention of the persons that appear in the Annex to Council Decision 2011/72/CFSP (1), and in Annex I to Council Regulation (EU) No 101/2011 (2), concerning restrictive measures directed

against certain persons, entities and bodies in view of the situation in Tunisia.

The Council intends to renew the restrictive measures provided for in Decision 2011/72/CFSP. The Council holds on its file new elements concerning all persons listed in the Annex to Decision 2011/72/CFSP and in Annex I to Regulation (EU) No 101/2011.The persons concerned are hereby informed that they may submit a request to the Council to obtain the information that relates to them, before 25 November 2019, to the following address:

Council of the European Union General Secretariat RELEX.1.C Rue de la Loi/Wetstraat 175 1048 Bruxelles/Brussel BELGIQUE/BELGIË Email: sanctions@consilium.europa.eu

Any observations received will be taken into account for the purpose of the Council’s periodic review, in accordance with Article 5 of Decision 2011/72/CFSP and Article 12(4) of Regulation (EU) No 101/2011.

(1) OJ L 28, 2.2.2011, p. 62.

(7)

Notice for the attention of the data subjects to whom the restrictive measures provided for in Council Decision 2011/72/CFSP and Council Regulation (EU) No 101/2011 concerning restrictive

measures directed against certain persons, entities and bodies in view of the situation in Tunisia apply

(2019/C 392/05)

The attention of data subjects is drawn to the following information in accordance with Article 16 of Regulation (EU) 2018/1725 of the European Parliament and of the Council (1).

The legal basis for this processing operation are Council Decision (CFSP) 2011/72/CFSP (2) and Council Regulation (EU)

No 101/2011 (3).

The controller of this processing operation is the Department RELEX.1.C in the Directorate-General for Foreign Affairs, Enlargement and Civil Protection — RELEX of the General Secretariat of the Council (GSC), that can be contacted at: Council of the European Union

General Secretariat RELEX.1.C Rue de la Loi/Wetstraat 175 1048 Bruxelles/Brussel BELGIQUE/BELGIË Email: sanctions@consilium.europa.eu

The GSC’s Data Protection Officer can be contacted at: Data Protection Officer

data.protection@consilium.europa.eu

The purpose of the processing operation is the establishment and updating of the list of persons subject to restrictive measures in accordance with Decision (CFSP) 2011/72/CFSP and Regulation (EU) No 101/2011.

The data subjects are the natural persons who fulfil the listing criteria as laid down in Decision (CFSP) 2011/72/CFSP and Regulation (EU) No 101/2011.

The personal data collected includes data necessary for the correct identification of the person concerned, the statement of reasons and any other data related thereto.

The personal data collected may be shared as necessary with the European External Action Service and the Commission. Without prejudice to restrictions pursuant to Article 25 of Regulation (EU) 2018/1725, the exercise of the rights of the data subjects such as the right of access, as well as the rights to rectification or to object will be answered in accordance with Regulation (EU) 2018/1725.

Personal data will be retained for 5 years from the moment the data subject has been removed from the list of persons subject to the restrictive measures or the validity of the measure has expired, or for the duration of court proceedings in the event they had been started.

Without prejudice to any judicial, administrative or non-judicial remedy, data subjects may lodge a complaint with the European Data Protection Supervisor in accordance with Regulation (EU) 2018/1725 (edps@edps.europa.eu).

(1) OJ L 295, 21.11.2018, p. 39.

(2) OJ L 28, 2.2.2011, p. 62.

(8)

EUROPEAN COMMISSION

Euro exchange rates (1)

18 November 2019 (2019/C 392/06)

1 euro =

Currency Exchange rate

USD US dollar 1,1061

JPY Japanese yen 120,55

DKK Danish krone 7,4726

GBP Pound sterling 0,85330

SEK Swedish krona 10,6603

CHF Swiss franc 1,0960

ISK Iceland króna 135,90

NOK Norwegian krone 10,0860

BGN Bulgarian lev 1,9558

CZK Czech koruna 25,593

HUF Hungarian forint 335,27

PLN Polish zloty 4,2915

RON Romanian leu 4,7744

TRY Turkish lira 6,3316

AUD Australian dollar 1,6242

Currency Exchange rate

CAD Canadian dollar 1,4622

HKD Hong Kong dollar 8,6593

NZD New Zealand dollar 1,7275

SGD Singapore dollar 1,5047

KRW South Korean won 1 289,14 ZAR South African rand 16,3463 CNY Chinese yuan renminbi 7,7629

HRK Croatian kuna 7,4400

IDR Indonesian rupiah 15 588,27

MYR Malaysian ringgit 4,5964

PHP Philippine peso 56,081

RUB Russian rouble 70,6242

THB Thai baht 33,443

BRL Brazilian real 4,6201

MXN Mexican peso 21,2907

INR Indian rupee 79,4260

(9)

COURT OF AUDITORS

Special Report No 21/2019

‘Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU’

(2019/C 392/07)

The European Court of Auditors hereby informs you that Special Report No 21/2019 ‘Addressing antimicrobial resistance: progress in the animal sector, but this health threat remains a challenge for the EU’ has just been published.

(10)

Special Report No 24/2019

‘Asylum, relocation and return of migrants: Time to step up action to address disparities between objectives and results’

(2019/C 392/08)

The European Court of Auditors hereby informs you that Special Report No 24/2019 ‘Asylum, relocation and return of migrants: Time to step up action to address disparities between objectives and results’ has just been published.

(11)

V

(Announcements)

PROCEDURES RELATING TO THE IMPLEMENTATION OF COMPETITION

POLICY

EUROPEAN COMMISSION

Prior notification of a concentration (Case M.9639 — CDC/EDF/Dalkia Investissement)

Candidate case for simplified procedure

(Text with EEA relevance) (2019/C 392/09)

1. On 11 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings: — Electricité de France (‘EDF’, France),

— Caisse des dépôts et consignations (‘CDC’, France),

— Dalkia Investissement SAS (‘Dalkia Investissement’, France), controlled by EDF.

EDF and CDC acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Dalkia Investissement.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— EDF and its subsidiaries are mainly active in the electricity sector, especially in the generation and wholesale of electricity, transportation and distribution of electricity in France and abroad. It is also active in the gas sector and in energy related services in France and abroad,

— CDC is a French public institution with a special legal status, active in the management of private funds to which public authorities wish to provide special protection and in the financing of public-interest investment projects (transport, environment, transmission of electricity, etc.),

— Dalkia Investissement is a holding company owning part of the shares of ELM SAS, which is responsible for the exploitation of the heat and cold networks of certain areas of the city of Lyon.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out

in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(12)

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

Case M.9639 — CDC/EDF/Dalkia Investissement

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301 Postal address: European Commission

Directorate-General for Competition Merger Registry

1049 Bruxelles/Brussel BELGIQUE/BELGIË

(13)

Prior notification of a concentration

(Case M.9343 — Hyundai Heavy Industries/Daewoo Shipbuilding & Marine Engineering)

(Text with EEA relevance) (2019/C 392/10)

1. On 12 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings: — Hyundai Heavy Industries Co., Ltd. (‘HHI’) (Korea),

— Daewoo Shipbuilding & Marine Engineering Co., Ltd. (‘DSME’) (Korea), controlled by the Korea Development Bank (‘KDB’).

HHI acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of DSME. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for HHI: a Korean company mainly active in the construction of commercial vessels, including oil tankers, containerships, liquefied natural gas (‘LNG’) carriers and liquefied petroleum gas (‘LPG’) carriers, military vessels, and offshore facilities and the production of marine engines,

— for DSME: a Korean company mainly active in the construction of commercial vessels including oil tankers, containerships, liquefied natural gas (‘LNG’) carriers and liquefied petroleum gas (‘LPG’) carriers and offshore facilities. 3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9343 — Hyundai Heavy Industries/Daewoo Shipbuilding & Marine Engineering.

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301 Postal address: European Commission

Directorate-General for Competition Merger Registry

1049 Bruxelles/Brussel BELGIQUE/BELGIË

(14)

Prior notification of a concentration (Case M.9461 — AbbVie/Allergan)

(Text with EEA relevance) (2019/C 392/11)

1. On 12 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).

This notification concerns the following undertakings: — AbbVie Inc., (‘AbbVie’, United States),

— Allergan plc (‘Allergan’, Ireland).

AbbVie acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— AbbVie is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in the United States. AbbVie is engaged in the development and commercialisation of innovative medicines in six main therapeutic areas: immunology (including autoimmune diseases), oncology, virology, neuroscience/central nervous system disorders, metabolic diseases and pain associated with endometriosis;

— Allergan is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in Ireland. Allergan is engaged in the development and commercialisation of medicines in four key therapeutic areas: medical aesthetics, eye care, neuroscience/central nervous system disorders and gastroenterology.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9461 — AbbVie/Allergan

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below: Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301 Postal address: European Commission

Directorate-General for Competition Merger Registry

1049 Bruxelles/Brussel BELGIQUE/BELGIË

(15)
(16)

Figure

Updating...

References

Updating...

Related subjects :